NewTimeSpace News: The CSRC has issued a filing notice for overseas issuance and listing to Red Avenue New Materials Group Co., Ltd., which plans to issue no more than 78,724,900 overseas listed ordinary shares for listing on the Stock Exchange of Hong Kong; the Company is required to report within 15 working days after the completion of the issuance and listing.
NewTimeSpace News: The CSRC has issued a filing notice for overseas issuance and listing to Suzhou Leadsynbio Technology Co., Ltd., which plans to issue no more than 18,271,600 overseas listed ordinary shares for listing on the Stock Exchange of Hong Kong, with 27 shareholders converting an aggregate of 47,665,277 domestic unlisted shares into overseas listed shares (full circulation); the Company is required to report within 15 working days after the completion of the issuance and listing.
NewTimeSpace News: On 28 August 2026, NEBULA ELECTRONICS (300648.SZ) announced that its board had approved a plan to issue H shares and list on the Main Board of the Hong Kong Stock Exchange, aiming to advance its internationalization strategy; the issuance and listing are subject to shareholders' meeting deliberation and approvals or filings from the CSRC, the SFC and the Stock Exchange, with no details finalized and significant uncertainty as to final implementation.
NewTimeSpace News: Medcaptain Medical Technology Co., Ltd.(02041.HK) officially launched its H-share IPO on 28 August 2026. The offer price is set at HK$15.420 per share, with 100 shares per board lot and an entry cost of approximately HK$1,557.55. The company is expected to be listed on the Main Board of the Hong Kong Stock Exchange on 7 September 2026. A total of 38.9106 million shares will be offered globally, including 10% for Hong Kong public offer and 90% for international offer. The total fundraising amount is about HK$600 million, with net proceeds of roughly HK$496 million. The offer ratio stands at approximately 7.22%, and the total share capital after issuance will be around 539 million shares.
NewTimeSpace News: On 27 August 2026, Dizal Pharmaceutical Co., Ltd. filed a listing application with HKEX, with Goldman Sachs and Huatai International as joint sponsors; its core product sunvozertinib is the world's first small-molecule EGFR-TKI approved for EGFR exon20ins-mutant lung cancer (approved in the US and included in the NRDL), and golidocitinib is the world's only JAK1 inhibitor approved for r/r PTCL; on 14 July 2026, the Company entered into a global exclusive license agreement with AstraZeneca for sunvozertinib, with an upfront payment of USD 600.0 million (the largest upfront in a single-asset license-out for a Chinese small-molecule drug to date), plus development milestone payments of up to USD 400.0 million and sales milestone payments of up to USD 500.0 million.
NewTimeSpace News: On 28 August 2026, Medcaptain Medical Technology Co., Ltd. (stock code: 02041) commenced its global offering of 38,910,600 H shares, comprising 3,891,100 H shares under the......
NewTimeSpace News: On 27 August 2026, Transwarp Technology (Shanghai) Co., Ltd. passed the HKEX listing hearing, with Haitong International as sole sponsor; by revenue, the Company is China's fifth-largest AI infrastructure software provider (2.7% market share in 2025) and the largest independent service provider, and the first database enterprise globally to pass TPC-DS audit; its products cover big data platforms, distributed databases, AI platforms and knowledge platforms, serving over 1,800 customers including 105 Fortune China 500 enterprises, with repeat purchase revenue from existing customers averaging over 70% of total revenue.
NewTimeSpace News: On 27 August 2026, Shanghai Vision Star Media Co., Ltd. filed a listing application with HKEX, with SPDB International as sole sponsor; by 2025 revenue, the Company was the fifth largest integrated marketing service provider and the largest brand-IP content marketing service provider in China; revenue reached RMB 8.3718 billion in 2025 (CAGR of 15.8% from 2023), serving over 2,000 clients including 69 China Fortune 500 enterprises; the Company has built the "Xinghe AI Full-Link Workbench" with peak daily token usage of approximately 1.7 billion; no stock code has been assigned at the filing stage.
NewTimeSpace News: On 27 August 2026, LEADERDRIVE (688017.SH) announced its proposal to conduct an initial public offering of H shares and list on the HKEX Main Board, with the relevant resolutions approved by the Board on 26 August 2026; the issuance remains subject to shareholders' meeting approval and filing, approval and/or authorization by the CSRC, HKEX and the SFC, with the company planning to complete it within 24 months from the date of shareholders' approval; specific details have not been finalized and implementation is subject to uncertainty.
NewTimeSpace News: On 27 August 2026, SHEIN-W (00625.HK) closed its H-share IPO subscription at noon; as of 11:10 a.m., total margin funds reached approximately HKD 6.465 billion, with the public offering covered approximately 4.66 times based on a public offering size of HKD 1.386 billion; the company is offering 280 million H shares at HKD 47.600-49.500 per share, implying gross proceeds of HKD 13.328-13.860 billion, and is expected to list on 1 September 2026.
NewTimeSpace News: On 27 August 2026, MECH MIND (09615.HK) closed its H-share IPO subscription at noon; as of 11:10 a.m., total margin funds reached approximately HKD 347.22 billion, with the public offering covered approximately 2,950.76 times based on a public offering size of HKD 118 million; the company is offering 23.14 million H shares at HKD 95.300-101.700 per share, implying gross proceeds of HKD 2.205-2.353 billion, and is expected to list on 1 September 2026.
NewTimeSpace News: On 26 August 2026, Zenshine Pharmaceuticals (Nanjing) Group Co., Ltd. filed a listing application with HKEX, with CICC as sole sponsor; its core product, sebaloxavir marboxil tablets, an influenza virus PA endonuclease inhibitor, obtained NDA approval for adult influenza in July 2025 and for adolescents in June 2026, and was officially launched in October 2025; the company has a pipeline of six small-molecule drug assets, distributes in China through Jumpcan Pharmaceutical and is expanding into the MENA region with Cigalah Medpharm.
NewTimeSpace News: On 25 August 2026, Cheuk Power International Holding Limited filed its application with the GEM of the HKEX, with Baihui Financial Holdings as sole sponsor; the Company is principally engaged in demolition works in Hong Kong as a main contractor with over 35 years of operating history, ranked third in the Hong Kong demolition works market by 2025 revenue (approximately 4.9% market share); demolition works accounted for approximately 93.6% of total revenue in fiscal 2026.
NewTimeSpace News: On 25 August 2026, Sublime China Information Co., Ltd. (301299.SZ) refiled its application with the HKEX, with Ping An Securities (Hong Kong) as sole sponsor; the Company is a commodity information services provider in China, ranking first in the energy commodities segment by 2025 revenue (approximately 31.9% market share) and second in the overall industry (12.4%), with operations covering 25 industries and over 120,000 information sources, and revenue of RMB 356.0 million in fiscal 2025.
NewTimeSpace News: JUNZHENG (03223.HK) opened flat on its listing debut, with the opening price of HKD 100.00 in line with the offer price; the shares were priced at HKD 100.00 each with 31,287,300 shares issued, 100 shares per board lot and net proceeds of approximately HKD 3.055 billion; the Company is a "storage + computing + analog" chip provider with products applied in automotive electronics, industrial and medical, AIoT and intelligent security surveillance devices.
Newtimespace News:Ugreen Group Limited filed its second‑time listing application with the Hong Kong Stock Exchange on August 25, with Huatai International acting as the sole sponsor. According to Frost & Sullivan, in 2025, the company ranked first in mainland China and globally by shipment volume in the general‑expansion tech consumer electronics market. By revenue, it took the top spot in mainland China and second place worldwide, with respective market shares of 2.6% and 1.5%. Its products are available in more than 180 countries and regions, with overseas revenue accounting for 66.9% of total revenue.
